Skip to main content

Table 5 Results of multivariate analyses

From: Single nucleotide polymorphisms in apoptosis pathway are associated with response to imatinib therapy in chronic myeloid leukemia

Risk factor Referent parameter Adverse parameter Univariate p value Multivariate p value HR (95 % CI)
MCR
 FAS (rs2234978) CT/TT CC 0.026 0.062 0.52 (0.26–1.03)
 Age, continuous 0.748 0.920 1.00 (0.99–1.01)
 Prior treatment No Yes 0.009 0.060 0.56 (0.30–1.03)
 ACA Absent Present 0.128 0.560 0.85 (0.50–1.45)
 Disease stage AP/BC CP 0.450 0.190 1.98 (0.72–5.46)
CCR
 FAS (rs2234978) CT/TT CC 0.036 0.100 0.56 (0.28–1.12)
 Age, continuous 0.796 0.910 0.99 (0.98–1.01)
 Prior treatment No Yes 0.016 0.074 0.57 (0.31–1.05)
 ACA Absent Present 0.496 0.330 0.77 (0.45–1.30)
 Disease stage AP/BC CP 0.399 0.060 2.48 (0.96–6.38)
MMR
 FAS (rs2234978) CT/TT CC 0.050 0.022* 0.53 (0.30–0.91)
 FASLG (rs763110) CT/TT CC 0.017 0.079 1.42 (0.96–2.11)
 Age, continuous 0.670 0.880 0.99 (0.98–1.01)
 Prior treatment No Yes 0.002 0.007** 0.44 (0.24–0.80)
 ACA Absent Present 0.097 0.490 0.81 (0.44–1.48)
 Disease stage AP/BC CP 0.235 0.062 2.48 (0.96–6.44)
MR4.5
 FAS (rs2234767) GA/GG AA 0.013 0.019* 0.43 (0.22–0.87)
 FAS (rs2234978) CT/TT CC 0.011 0.003** 0.45 (0.26–0.77)
 Age, continuous 0.911 0.470 0.99 (0.98–1.01)
 Prior treatment No Yes 0.011 0.051 0.50 (0.25–1.00)
 ACA Absent Present 0.110 0.930 0.97 (0.46–2.02)
 Disease stage AP/BC CP 0.316 0.110 3.17 (0.76–13.17)
LOR
 APAF1 (rs1439123) TT CT/CC 0.011 0.174 0.36 (0.08–1.57)
 FAS (rs2234767) GA/GG AA 0.034 0.177 2.21 (0.70–7.02)
 Age, continuous   0.875 0.99 (0.96–1.03)
 Prior treatment No Yes 0.062 0.538 1.47 (0.43–5.06)
 ACA Absent Present 0.973 0.918 1.08 (0.24–4.89)
 Disease stage AP/BC CP 0.432 0.607 1.77 (0.20–15.43)
TF
 CASP10 (rs13006529) TA/AA TT 0.025 0.049* 0.57 (0.32–0.99)
 Age, continuous 0.978 0.869 0.99 (0.97–1.02)
 Prior treatment No Yes 0.039 0.040* 1.94 (1.03–3.67)
 ACA Absent Present 0.257 0.483 1.31 (0.61–2.81)
 Disease stage AP/BC CP 0.001 0.093 0.47 (0.20–1.13)
PFS
 FASLG (rs763110) CT/TT CC 0.001 0.003** 0.04 (0.01–0.36)
 Age, continuous 0.765 0.260 0.98 (0.94–1.02)
 Prior treatment No Yes 0.235 0.053 3.28 (0.98–10.90)
 ACA Absent Present 0.093 0.018* 4.36 (1.29–14.71)
 Disease stage AP/BC CP 0.873 0.251 3.58 (0.41–31.68)
OS
 CASP10 (rs13006529) TA/AA TT 0.019 0.050* 0.25 (0.06–1.00)
 FASLG (rs763110) CT/TT CC 0.020 0.046* 0.12 (0.01–0.97)
 Age, continuous 0.787 0.300 0.97 (0.92–1.02)
 Prior treatment No Yes 0.225 0.170 2.75 (0.65–11.64)
 ACA Absent Present 0.441 0.175 3.07 (0.61–15.51)
 Disease stage AP/BC CP 0.917 0.377 2.94 (0.27–32.15)
  1. ACA additional cytogenetic abnormality, HR hazard ratio, SNP single nucleotide polymorphism, MCR major cytogenetic response, CCR complete cytogenetic response, MMR major molecular response, MR4.5 molecular response with 4.5 log reduction, LOR loss of response, TF treatment failure, PFS progression free survival, OS overall survival, APAF1 apoptotic peptidase activating factor 1, CASP10 caspase 10, FAS Fas cell surface death receptor, FASLG Fas ligand (TNF receptor superfamily member 6)
  2. * P < 0.05/** P < 0.01